| Item type |
学術雑誌論文 / Journal Article(1) |
| タイトル |
|
|
タイトル |
Coronary Computed Tomography Angiography for Observation of Stabilized Coronary Arterial Plaque after “Drug Intervention”: A Case Report |
|
言語 |
en |
| 言語 |
|
|
言語 |
eng |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
strike early-strike strong lipid-lowering strategy |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
low-density lipoprotein cholesterol |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
proprotein convertase subtilisin/kexin type 9 inhibitor |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
statins |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
| アクセス権 |
|
|
アクセス権 |
open access |
|
アクセス権URI |
http://purl.org/coar/access_right/c_abf2 |
| 著者 |
Lu, Tianyang
Yazawa, Hiroko
Sakuma, Masashi
Inoue, Riri
Hashimoto, Ryota
Hirose, Suguru
Waku, Ryutarou
Yonezawa, Yutaka
Koyabu, Yota
Nishino, Setsu
Kanaya, Tomoaki
Toyoda, Shigeru
|
| 書誌情報 |
en : Dokkyo Medical Journal
巻 4,
号 3,
p. 260-267,
発行日 2025-06-25
|
| 記事種別 |
|
|
値 |
Case Report |
| 内容記述 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
A 54-year-old woman with unstable angina underwent coronary stent deployment. She was started on rosuvastatin therapy before undergoing percutaneous coronary intervention (PCI). However, arriving at lowdensity lipoprotein cholesterol (LDL-C) levels lower than 70 mg/dL required more than a month of treatment. This was accomplished by increasing the rosuvastatin dose by 10 mg and adding ezetimibe. Chronic-phase coronary computed tomography angiography (CCTA) did not show stent restenosis but revealed plaque progression in the left main trunk (LMT). A combination of rosuvastatin, ezetimibe, and the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor was administered to promote regression of the plaque. Followup CCTA performed 12 months after the initial scan showed regression of the LMT plaque and the appearance of new calcification in the proximal plaque of the left anterior descending (LAD) artery. The aggressive lipid-lowering strategy that combined rosuvastatin, ezetimibe, and a PCSK9 inhibitor successfully achieved plaque regression without the occurrence of cardiovascular events. |
|
言語 |
en |
| 出版者 |
|
|
出版者 |
Dokkyo Medical Society |
| ISSN |
|
|
収録物識別子タイプ |
EISSN |
|
収録物識別子 |
2436-522X |
| 書誌レコードID |
|
|
収録物識別子タイプ |
NCID |
|
収録物識別子 |
AA12941861 |
| DOI |
|
|
関連タイプ |
isIdenticalTo |
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
https://doi.org/10.51040/dkmj.2024-048 |
| 出版タイプ |
|
|
出版タイプ |
VoR |
|
出版タイプResource |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
DKMJ-4-3-12.pdf (972 KB)
.png)
